Darusentan is primarily investigated for its potential therapeutic applications in managing cardiovascular conditions, particularly resistant hypertension. It functions as an endothelin receptor antagonist, targeting the endothelin system, which plays a significant role in regulating vascular tone and blood pressure. By blocking endothelin receptors, it helps to relax blood vessels, thereby reducing blood pressure in patients who do not respond adequately to standard antihypertensive treatments. Its application is particularly relevant in cases where traditional therapies fail to achieve desired blood pressure control, offering a potential alternative for improved cardiovascular outcomes. Research continues to explore its efficacy and safety in broader patient populations.